Actively Recruiting
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Led by Mansa · Updated on 2025-12-17
50
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
CONDITIONS
Official Title
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of MODY confirmed by genetic testing
- Hemoglobin A1c greater than 6.5%
You will not qualify if you...
- History of anaphylaxis to GLP-1 receptor agonists
- Currently taking GLP-1 receptor agonists
- Using stimulant class medications
- History of bariatric surgery
- Personal or family history of cancer, especially medullary thyroid cancer
- Personal history of pancreatitis or genetic variants increasing pancreatitis risk
- Known active kidney disease
- Severe hypoglycemia with glucose less than 50 mg/dL within 3 months before enrollment
- Hemoglobin A1c greater than 10.0%
- Diabetic ketoacidosis episode in the past 3 months
- Currently pregnant
- BMI less than 18.5 kg/m2, or for pediatric patients, BMI below the 5th percentile
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Actively Recruiting
Research Team
M
Mansa Krishnamurthy, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here